Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06839976 · ClinicalTrials.gov registry record · Phase 1
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
A Phase 1 study of Systemic Lupus Erythematosus (SLE) and Lupus, sponsored by Children's Hospital of Philadelphia.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06839976: Recruiting Phase 1 study of Systemic Lupus Erythematosus (SLE) and Lupus, sponsored by Children's Hospital of Philadelphia.
NCT06839976 is a Phase 1 study of Systemic Lupus Erythematosus (SLE) and Lupus that is actively recruiting participants, run by Children's Hospital of Philadelphia. The registered enrollment target is 24 participants, below the 1,063-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06839976, a Phase 1 study of Systemic Lupus Erythematosus (SLE) and Lupus, is actively recruiting participants, sponsored by Children's Hospital of Philadelphia.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE). Phase 1 will evaluate the safety of CART19 in 6-12 patients with Systemic lupus erythematosus (SLE). There is no planned dose escalation, but a dose de-escalation will be made based on the incidence of Dose Limiting Toxicities. Phase 2 will evaluate the efficacy and further evaluate the safety of CART19 in this population.
Primary Outcome
Frequency of the dose limiting toxicities of CART19
Conditions Studied
Interventions
- BIOLOGICAL CART19
Study Locations (1)
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-05-06 |
| Est. Completion | 2030-02-28 |
| Phase | Phase 1 |
What NCT06839976 shows while recruiting
NCT06839976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,063-participant average among 14 other Systemic Lupus Erythematosus (SLE) trials with a reported enrollment target (98% lower).
The record links to 7 conditions, with Systemic Lupus Erythematosus (SLE) appearing as the primary indexed condition, and to 1 intervention - of which CART19 is the first listed.
NCT06839976 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06839976 about?
NCT06839976 is a clinical study titled "CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus". This is a single-center, single-arm, open-label phase 1/2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE). Phase 1 will evaluat...
What is the current status of trial NCT06839976?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-05-06. Estimated completion is 2030-02-28.
What conditions does trial NCT06839976 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus (SLE), Lupus, SLE, Cell Therapy, Lupus Nephritis (LN).
What interventions are being tested in trial NCT06839976?
The interventions under investigation include: CART19 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06839976?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06839976 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus (SLE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06839976's enrollment target sits among peer trials
24 13th of 14 higher than 2 of 14 other Systemic Lupus Erythematosus (SLE) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus (SLE) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
RECRUITING · Phase 1
-
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RECRUITING · Phase 1
-
UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients
RECRUITING · Phase 1
-
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
RECRUITING
-
Research Accelerated by You Lupus Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI